Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MYL

Mylan (MYL) Stock Price, News & Analysis

Mylan logo

About Mylan Stock (NASDAQ:MYL)

Advanced Chart

Key Stats

Today's Range
$15.86
$15.86
50-Day Range
$14.37
$15.86
52-Week Range
$12.75
$23.11
Volume
4,016 shs
Average Volume
6.49 million shs
Market Capitalization
$8.59 billion
P/E Ratio
29.92
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Receive MYL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mylan and its competitors with MarketBeat's FREE daily newsletter.

MYL Stock News Headlines

Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
Dog competition comes to Mylan Park
See More Headlines

MYL Stock Analysis - Frequently Asked Questions

Mylan (NASDAQ:MYL) released its quarterly earnings data on Friday, November, 6th. The company reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.16 by $0.15. The firm's revenue was up .4% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mylan investors own include Bristol-Myers Squibb (BMY), Meta Platforms (META), NVIDIA (NVDA), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Netflix (NFLX) and Micron Technology (MU).

Company Calendar

Last Earnings
11/06/2020
Today
5/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MYL
Fax
N/A
Employees
35,000
Year Founded
N/A

Profitability

Trailing P/E Ratio
29.92
Forward P/E Ratio
3.55
P/E Growth
2.01
Net Income
$16.80 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.50 billion
Cash Flow
$8.76 per share
Price / Cash Flow
1.81
Book Value
$23.02 per share
Price / Book
0.69

Miscellaneous

Free Float
N/A
Market Cap
$8.59 billion
Optionable
Optionable
Beta
1.45
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:MYL) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners